aldosterone blockers, spironolactone
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2014 Apr 10;370(15):1383-92 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, diastolic (preserved ejection fraction) The Use of
aldosterone blockers, spironolactone
As Treatment, Chronic
Is equal Than
placebo
To modify clinical events (cardiovascular death or hospitalization for heart failure) at 3 years: 18.6% spironol. VS 20.4% placebo). Only hospitalizations for HF were reduced (12% spironol. VS 14.2% placebo) but not hospitalizations by any reason
Heart. 2017 Aug 5. pii: heartjnl-2017-311652. doi: 10.1136/heartjnl-2017-311652. [Epub ahead of prin Meta-Analysis
IN heart failure, chronic, diastolic (preserved ejection fraction) The Use of
various medical treatments: angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), beta blockers, aldosterone blockers, spironolactone
As Treatment, Chronic
Is equal Than
placebo
To modify survival (except beta blockers, associated with reduced all-cause and cardiac deaths, (RR: 0.78) or reduce rehospitalizations or improve functional capacity
N Engl J Med. 1999 Sept 2;341(10):709-17 Randomized Controlled Trial
IN heart failure, chronic, systolic, severe The Use of
aldosterone blockers, spironolactone, added to loop diuretics and ACEI
As Treatment, Chronic
Is better Than
placebo
To reduce overall mortality, at 2 years: 35% in intv. VS 46% in ctrl. Reduce cardiac hospitalizations and significantly improve NYHA class